

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY,
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH,
Patent Owner.

Case No. IPR2018-01712
Patent No. 9,884,908

**PETITIONER'S RESPONSE TO TEVA'S SUPPLEMENTAL BRIEF
REGARDING *FOX FACTORY, INC. v. SRAM, LLC***

Table of Contents

I. Teva Failed to Establish that Amino Acid Sequence Is Insignificant 1

II. Teva Failed to Meet Its Burden of Establishing Coextensiveness..... 2

III. Teva Failed to Distinguish *Fox Factory*..... 3

IV. Teva Failed to Address Its Unchallenged Claims Reciting Sequence 4

GLOSSARY

FDA	U.S. Food and Drug Administration
IPR	<i>Inter partes</i> review
<i>Italicized text</i>	Emphasis added unless otherwise indicated
Lilly or Petitioner	Eli Lilly and Company
pM	picomolar
Teva or Patent Owner	Teva Pharmaceuticals International GmbH
'908 patent	U.S. Patent No. 9,884,908 (Ex. 1001)
'045 patent	U.S. Patent No. 8,586,045 (Ex. 1001 in IPR2018-01710)
'614 patent	U.S. Patent No. 9,340,614 (Ex. 1001 in IPR2018-01422)
'614 Hearing Tr.	Record of Oral Hearing (Paper 71 in IPR2018-01422)
'951 patent	U.S. Patent No. 9,266,951 (Ex. 1001 in IPR2018-01423)
'881 patent	U.S. Patent No. 9,346,881 (Ex. 1001 in IPR2018-01424)
'794 patent	U.S. Patent No. 8,007,794 (Ex. 2024)

I. Teva Failed to Establish that Amino Acid Sequence Is Insignificant

Having represented to the FDA that it engineered Ajovy[®]'s amino acid sequence to achieve its therapeutic profile, Teva's repeated failure to address the criticality of sequence confirms that no presumption applies. Ex. 1320, 8-9; Reply, 22-23; *Fox Factory, Inc. v. SRAM, LLC*, 944 F.3d 1373, 1375-76 (Fed. Cir. 2019). Teva's mere attorney argument that sequence is insignificant is baseless. Br., 5.

Depending on their specific sequence, anti-CGRP antibodies within the broad scope of the claims would have (1) binding affinity *orders of magnitude worse* than Ajovy[®] and Emgality[®], (2) strong effector functions having the *undesired side effect of killing cells*, and/or (3) an antibody subclass *never successfully used before* in any FDA-approved antibody. Reply, 22-24; Ex. 1301, 34:9-35:1, 101:15-104:19; Ex. 1018, ¶¶199-200. These unclaimed features would lead to materially different properties (*e.g.*, no efficacy or significant adverse events) compared to Emgality[®] and Ajovy[®] and were identified by the FDA as directly bearing on "*critical quality attributes*" (CQAs). Ex. 2216, 17; Ex. 1320, 6-9.

Teva's unsupported argument that "sequences are not driving the praise" (because Emgality[®] and Ajovy[®] have different sequences) is therefore inconsistent with the admissions of its expert, contrary to its representations to FDA, and contrary to the fundamental principle of antibody biology that sequence determines function. Br., 5; Ex. 1063, 59, 63; Ex. 1062, 41; Ex. 1301, 93:14-20; Reply, 22-23.

II. Teva Failed to Meet Its Burden of Establishing Coextensiveness

In an effort to argue away its admission that Ajoyv[®] and Emgality[®] are *not* “coextensive” with its overbroad claims, Teva contends they form a representative number of species within the claimed genus. ’614 Hearing Tr., 63; Br. 2, n.1, 5-7. But this is mere attorney argument, unsupported by any evidence.¹

Teva’s argument also lacks merit. Two sequence-engineered, FDA-approved antibody drugs are *not* representative of broad genus claims seeking to cover using *all* humanized anti-CGRP IgG antibodies, *regardless of sequence*, for treating migraine (among at least 250 other forms of headache). Ex. 1304, 74:17-75:12. Indeed, as held in *Celltrion, Inc. v. Genentech, Inc.*, a sequence-engineered, FDA-approved antibody drug lacks nexus to even sub-genus claims reciting specific mutations. IPR2017-01374, Paper 85 at 45, 48 (PTAB Nov. 29, 2018) (relying on “one (or a small number of) species” is “*inadequate proof*” for nexus). Teva’s claims are much broader because they are not limited by sequence. Reply, 22-23.

¹ Teva’s representative species argument is waived, as Teva failed to raise it before the oral argument. *See* POR, 54-55; Sur-reply, 27; *Cablz, Inc. v. Chums, Inc.*, 708 F. App’x 1006, 1011-12 (Fed. Cir. 2017). Moreover, Teva’s new arguments alleging praise and success for Alder’s antibody are also waived, as Teva argued Alder *only* in the context of a license agreement. POR, 62-63.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.